Academy of Oncology Nurse & Patient Navigators and the American Cancer Society (ACS) Forge Partnership

Best Practices in Lung Cancer – November 2017 Vol 8

Categories:

In the News

Alliance will advance educational and professional development opportunities for ACS Oncology Navigators

It has been proved that teamwork is vital in the battle against cancer. This is a fact that the Academy of Oncology Nurse & Patient Navigators (AONN+) and the American Cancer Society (ACS) recently validated when they entered into a National Alliance Partnership Program.

Under this program—which brings together 2 organizations that are strongly aligned in their missions and values—ACS oncology patient navigators will have access to all AONN+ member resources, including the Oncology Patient Navigator–Certified Generalist™ (OPN-CG) certification exam when requirements are met.

With more than 6000 members, AONN+ is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators.

The ACS is a global grassroots force of 2 million volunteers saving lives in every community. As the largest voluntary health organization, the Society’s efforts have contributed to a 25% decline in the cancer death rate in the United States since 1991, driven by less smoking, better treatments, and earlier detection.

“AONN+’s collective resources will help empower ACS’ navigators with the education and skillsets necessary to further their professional competencies,” says Lillie Shockney, RN, BS, MAS, ONN-CG, Cofounder and Program Director, AONN+. “There’s little question that certification for oncology navigators is an issue about which both AONN+ and ACS are passionate.”

“We are excited and committed to further develop a synergistic alliance with ACS that is mutually structured to provide interactive opportunities to experience knowledge sharing, increase innovation, and enhance collaborative engagement to pursue superior quality cancer care,” says AONN+’s Danelle Johnston, RN, MSN, BSN, ONN-CG, OCN, CBCN, Chief Nursing Officer and Senior Director of Strategic Planning and Initiatives.

“A cancer diagnosis can be the most overwhelming experience a person may ever face in his or her lifetime. The journey can be challenging for patients and their caregivers to manage,” says Katherine Sharpe, MTS, Senior Vice President, Patient and Caregiver Support for the ACS. “We are thrilled that ACS patient navigators will have access to the wealth of resources through our partnership with AONN+. This partnership will support our navigators in their efforts to help improve the quality of life for cancer patients and their caregivers as they face the psychosocial, emotional, and financial aspects of their cancer experience.”

Related Articles
FDA Approves New 400 mg Every-6-Weeks Dosing Regimen of Keytruda for All Indications
Web Exclusives
On April 29, 2020, the FDA accelerated the approval of the oral poly ADP-ribose polymerase (PARP) inhibitor niraparib (Zejula; GlaxoSmithKline) as the first and only drug approved for first-line maintenance therapy of all patients with advanced ovarian cancer—including epithelial ovarian, fallopian tube, or primary peritoneal cancer—who have had a complete or partial response to first-line platinum-based chemotherapy.
Zejula First PARP Inhibitor Approved as First-Line Maintenance Treatment for All Patients with Ovarian Cancer
Web Exclusives
On April 29, 2020, the FDA accelerated the approval of the oral poly ADP-ribose polymerase (PARP) inhibitor niraparib (Zejula; GlaxoSmithKline) as the first and only drug approved for first-line maintenance therapy of all patients with advanced ovarian cancer—including epithelial ovarian, fallopian tube, or primary peritoneal cancer—who have had a complete or partial response to first-line platinum-based chemotherapy.
Jelmyto First FDA-Approved Therapy for Low-Grade Upper-Tract Urothelial Cancer
Web Exclusives
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country